News headlines about XOMA Corporation (NASDAQ:XOMA) have trended positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XOMA Corporation earned a coverage optimism score of 0.30 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.8782122947896 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- The Charles Schwab Corporation (SCHW) Stake Maintained by Sanctuary Wealth Advisors LLC (expressnewsline.com)
- Chiasma, Inc. (CHMA) noted a price change of -5.26% and XOMA Corporation (XOMA) closes with a move of 0.55% – Stocks Gallery (stocksgallery.com)
- XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 (finance.yahoo.com)
- XOMA Corporation to Post Q3 2017 Earnings of ($0.80) Per Share, Wedbush Forecasts (XOMA) (americanbankingnews.com)
- Xoma Corp Receives a Hold from Wedbush – Analyst Ratings (analystratings.com)
Shares of XOMA Corporation (XOMA) traded up 0.67% during mid-day trading on Friday, reaching $7.52. The company had a trading volume of 12,514 shares. The firm has a 50-day moving average price of $7.25 and a 200-day moving average price of $6.39. The stock’s market capitalization is $57.14 million. XOMA Corporation has a 1-year low of $3.96 and a 1-year high of $14.00.
XOMA has been the topic of several recent analyst reports. Zacks Investment Research cut shares of XOMA Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. HC Wainwright began coverage on XOMA Corporation in a research note on Monday, June 12th. They issued a “buy” rating and a $15.00 price target for the company. ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, Wedbush reaffirmed a “hold” rating on shares of XOMA Corporation in a research note on Monday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.67.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.